In a male kidney‑transplant recipient on tacrolimus, how should the tacrolimus dose be adjusted and monitored when initiating prostate‑cancer therapy with relugolix (GnRH antagonist) and darolutamide (androgen‑receptor antagonist)?

Tacrolimus Management with Relugolix and Darolutamide in Kidney Transplant Recipients

No dose adjustment of tacrolimus is required when initiating relugolix and darolutamide, but intensify therapeutic drug monitoring with trough levels measured within 3-5 days of starting these agents and weekly thereafter until stable levels are confirmed.

Drug Interaction Assessment

Relugolix

Relugolix is a GnRH antagonist that does not significantly interact with tacrolimus. While relugolix is a substrate of P-glycoprotein (P-gp), it does not inhibit or induce CYP3A4—the primary metabolic pathway for tacrolimus 1. Clinical studies demonstrate that relugolix maintains testosterone suppression when combined with other agents without requiring dose adjustments 2, 3. The pharmacokinetic profile of relugolix remains stable over time when used in combination therapy 3.

Darolutamide

Darolutamide presents a mild interaction concern. According to FDA labeling, darolutamide is primarily metabolized by CYP3A4 and is a substrate of P-gp 4. Importantly, when darolutamide was studied with midazolam (a CYP3A4 substrate), it decreased midazolam exposure by approximately 30% 4, suggesting darolutamide acts as a weak CYP3A4 inducer rather than an inhibitor. This could theoretically reduce tacrolimus levels slightly, though the effect is modest.

Monitoring Strategy

Following KDIGO guidelines, measure tacrolimus trough levels (C0) whenever there is a change in medication or patient status that may affect blood levels 5. This is a strong recommendation (1B evidence) 5.

Specific Monitoring Protocol:

• Baseline: Obtain tacrolimus trough level before starting prostate cancer therapy
• Days 3-5: First trough level after initiating relugolix/darolutamide
• Weekly: Continue weekly monitoring for 3-4 weeks
• Bi-weekly: If levels remain stable, transition to every 2 weeks for the next month
• Return to standard: Resume routine monitoring schedule (every 2-3 months) once stability confirmed 5

Target tacrolimus trough levels depend on time post-transplant. For stable, long-term kidney transplant recipients, maintain trough levels of 4-6 ng/mL for monotherapy or 3-5 ng/mL if combined with other immunosuppressants 6.

Dose Adjustment Approach

Initial approach: No preemptive dose change. Start with current tacrolimus dose and adjust based on measured levels 5.

If Levels Decrease (due to mild CYP3A4 induction by darolutamide):

• Increase tacrolimus dose by 10-20% increments
• Recheck trough level in 3-5 days
• Continue adjusting until target range achieved

If Levels Increase (unlikely but possible):

• Decrease tacrolimus dose by 10-20% increments
• Recheck trough level in 3-5 days

Critical Safety Considerations

Graft Protection Priority

Continue calcineurin inhibitors rather than withdraw them 5—this is fundamental to preventing rejection. The KDIGO guidelines emphasize that CNI continuation is essential for graft survival (2B recommendation) 5.

Monitor for Rejection

• Measure serum creatinine at each tacrolimus level check 5
• Any unexplained rise in creatinine warrants investigation for rejection or nephrotoxicity 5
• Consider biopsy if kidney function declines 5

Cardiovascular Monitoring

Both tacrolimus and darolutamide can affect cardiovascular parameters:

• Monitor blood pressure regularly—tacrolimus commonly causes hypertension 1
• Monitor potassium levels—tacrolimus causes hyperkalemia 1
• QT interval monitoring: Tacrolimus may prolong QT interval; obtain baseline ECG and monitor electrolytes (magnesium, potassium, calcium) periodically 1

Neurotoxicity Surveillance

Watch for tacrolimus neurotoxicity symptoms (tremors, headache, mental status changes), which may occur even at therapeutic levels 1. Consider dose reduction if neurotoxicity develops.

Common Pitfalls to Avoid

1. Don't assume no interaction means no monitoring: Even without significant drug interactions, medication changes warrant increased surveillance per transplant guidelines 5

2. Don't rely solely on trough levels in all patients: While C0 monitoring is standard 5, patients with low C0/dose ratios may have unexpectedly high peak concentrations and be at risk for toxicity despite "therapeutic" troughs 7, 8. If toxicity symptoms develop with therapeutic troughs, consider AUC-based monitoring.

3. Don't forget renal function monitoring: Tacrolimus nephrotoxicity is cumulative; measure creatinine with each level check 5

4. Don't overlook the cancer treatment priority: These prostate cancer therapies improve survival in metastatic disease 9. Ensure tacrolimus adjustments don't delay or compromise cancer treatment.

Coordination of Care

Inform both the transplant team and oncology team about all medication changes. The KDIGO guidelines explicitly state that clinicians responsible for patient care must be made aware of any change in prescribed immunosuppressive drugs 5.